After Years of Trial and Error, Biotech is Seeing More Successes Than Ever

<p>John Crowley, Chairman &amp; Former CEO of Amicus Therapeutics, joins the show to discuss the strides the biotech industry has made in therapies for rare genetic diseases and the industry landscape going forward. </p><br><p>This interview originally aired as part of Wharton Business Daily's Business of Healthcare special.</p><br /><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>